1. VH mutation status and VDJ rearrangement structure in mantle cell lymphoma: correlation with genomic aberrations, clinical characteristics, and outcome
by Dirk Kienle, Alexander Kröber, Tiemo Katzenberger, German Ott, Elke Leupolt, Thomas F. E. Barth, Peter Möller, Axel Benner, Annett Habermann, Hans Konrad Müller-Hermelink, Martin Bentz, Peter Lichter, Hartmut Döhner, and Stephan Stilgenbauer
Blood
Volume 102(8):
October 15, 2003
©2003 by American Society of Hematology

2. Mean ZAP70 expression levels.
Mean ZAP70 expression levels. Mean relative ZAP70 expression levels in patients with VH-mutated MCL (n = 11) and -unmutated MCL (n = 11) and in patients with VH-mutated CLL (n = 3) and -unmutated CLL (n = 3). Mean relative ZAP70 expression levels are indicated by columns; error bars represent the corresponding standard deviation.
Dirk Kienle et al. Blood 2003;102:
©2003 by American Society of Hematology

3. Kaplan-Meier survival curves.
Kaplan-Meier survival curves. Curves compare VH-mutated and -unmutated MCL. Median survival times were 45.1 months in the VH-mutated subgroup (n = 30) and 38.4 months in the VH-unmutated subgroup (n = 75) (P = .67).
Dirk Kienle et al. Blood 2003;102:
©2003 by American Society of Hematology

4. Kaplan-Meier survival estimates.
Kaplan-Meier survival estimates. Estimates compare V3-21 patients with the remaining MCL patients. Median survival times were months in the V3-21 group (n = 12) and 36.6 months in the group with the remaining patients (n = 93) (P = .08).
Dirk Kienle et al. Blood 2003;102:
©2003 by American Society of Hematology